Rein Therapeutics (RNTX) Equity Average (2017 - 2025)
Rein Therapeutics (RNTX) has disclosed Equity Average for 9 consecutive years, with $31.6 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 57.82% to $31.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.6 million through Dec 2025, down 57.82% year-over-year, with the annual reading at $35.7 million for FY2025, 53.3% down from the prior year.
- Equity Average for Q4 2025 was $31.6 million at Rein Therapeutics, down from $47.1 million in the prior quarter.
- The five-year high for Equity Average was $98.1 million in Q3 2024, with the low at $12.0 million in Q3 2023.
- Average Equity Average over 5 years is $47.7 million, with a median of $47.1 million recorded in 2021.
- The sharpest move saw Equity Average plummeted 58.89% in 2023, then skyrocketed 717.99% in 2024.
- Over 5 years, Equity Average stood at $47.0 million in 2021, then plummeted by 56.05% to $20.7 million in 2022, then skyrocketed by 165.0% to $54.7 million in 2023, then soared by 36.65% to $74.8 million in 2024, then tumbled by 57.82% to $31.6 million in 2025.
- According to Business Quant data, Equity Average over the past three periods came in at $31.6 million, $47.1 million, and $48.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.